Mildronate, 500 mg capsules, 60 pcs.

Composition

1 capsule of meldonium dihydrate 500 mg

Auxiliary substances:

potato starch – 27.2 mg,

colloidal silicon dioxide-10.8 mg,

calcium stearate-5.4 mg.

Capsule shell composition:

titanium dioxide (E 171) – 2%,

gelatin-98%.

Pharmacological action

of Mildronate-cardioprotective, antihypoxic, angioprotective, antianginal.

Under conditions of increased stress, Mildronate restores the balance between the delivery and demand of cells for oxygen, eliminates the accumulation of toxic metabolic products in cells, protecting them from damage; it has a tonic effect. As a result of its application, the body acquires the ability to withstand the load and quickly restore energy reserves.

Thanks to these properties, Mildronate is used to treat various disorders of the cardiovascular system, blood supply to the brain, as well as to increase physical and mental performance. As a result of a decrease in the carnitine concentration, gamma-butyrobetaine, which has vasodilating properties, is intensively synthesized.

In the case of acute ischemic myocardial injury, Mildronate slows down the formation of a necrotic zone, shortens the rehabilitation period. In heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of the cerebral circulation, it improves blood circulation in the focus of ischemia, promotes blood redistribution in favor of the ischemic area. It is effective in the case of vascular and dystrophic fundus pathology. The drug eliminates functional disorders of the central nervous system in patients with chronic alcoholism and withdrawal symptoms.

Pharmacokinetics

When taken orally, it is well absorbed. Bioavailability is about 78%. Cmax is reached in 1-2 hours. Biotransformed in the body with the formation of two main metabolites that are excreted by the kidneys. T1 / 2 — 3-6 hours and depends on the dose.

Indications

• : hemophthalmos and retinal hemorrhages of various etiologies;
• thrombosis of the central retinal vein and its branches;
• IHD; cerebral circulation disorders;
• retinopathy of various etiologies (diabetic, hypertensive).

Use during pregnancy and lactation

The safety of using the drug during pregnancy has not been established. In order to avoid possible adverse effects on the fetus, Mildronate should not be prescribed during pregnancy.

It is not known whether meldonium dihydrate is excreted in breast milk. If it is necessary to use Mildronate during lactation, breast-feeding should be discontinued.

Contraindications

Hypersensitivity to the Active ingredient and other components of the drug, increased intracranial pressure (with impaired venous outflow, intracranial tumors), age up to 18 years (efficacy and safety have not been established), pregnancy, breast-feeding. With caution:For liver and/or kidney diseases.

Side effects

• increased intracranial pressure (including venous outflow disorders, intracranial tumors);
• age up to 18 years (efficacy and safety have not been established);
• pregnancy;
• lactation (breastfeeding);
• hypersensitivity to the Active ingredient and other components of the drug.

The drug should be used with caution in patients with liver and/or kidney diseases.

Interaction

Mildronate enhances the effect of coronary dilators, some antihypertensive drugs, and cardiac glycosides.

Mildronate can be combined with prolonged forms of nitrates, other antianginal drugs, anticoagulants and antiplatelet agents, antiarrhythmics, diuretics and bronchodilators.

Due to the possible development of tachycardia and hypotension, caution should be exercised when combined with nitroglycerin (for sublingual use) and antihypertensive agents (especially alpha-blockers and short-acting forms of nifedipine).

How to take, course of administration and dosage

Due to the possibility of developing an excitatory effect, the drug is recommended to be used in the morning and no later than 17.00 (when taken several times a day).

In case of coronary heart disease (angina pectoris, myocardial infarction), chronic heart failure as part of complex therapy, the drug is prescribed orally at a dose of 0.5-1 g/day, the frequency of application is 1-2 times/day. The course of treatment is 4-6 weeks.

For dyshormonal cardiomyopathy Mildronate as part of complex therapy is prescribed orally at 500 mg / day. The course of treatment is 12 days.

In subacute disorders of the cerebral circulation (stroke and cerebrovascular insufficiency) after the end of the course of injection therapy with Mildronate, they continue to take 0.5-1 g/day orally as part of complex therapy, using the entire dose once or dividing it into 2 doses. The course of treatment is 4-6 weeks.

In chronic disorders of cerebral circulation, the drug is taken as part of a complex therapy inside 0.5 g / day. The general course of therapy is 4-6 weeks. Repeated courses are possible after consulting a doctor (usually 2-3 times a year).

With reduced performance, mental and physical overstrain (including athletes) assign inside 500 mg 2 times/day. The course of treatment is 10-14 days. If necessary, the therapy is repeated after 2-3 weeks.

Athletes are recommended to apply 0.5-1 g 2 times / day before training. The duration of the course during the preparatory period is 14-21 days, during the competition period-10-14 days.

Withdrawal symptoms in chronic alcoholism (in combination with specific alcoholism therapy) the drug is prescribed orally at 500 mg 4 times a day. The course of treatment is 7-10 days.

Overdose

Symptoms: reduced blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.

Treatment: conducting symptomatic therapy.

Special instructions

Patients with chronic liver and kidney diseases should exercise caution when using the drug for a long time.

Use in pediatrics

There are insufficient data on the use of Mildronate in children and adolescents under 18 years of age.

Influence on the ability to drive motor vehicles and manage mechanisms

There are no data on the adverse effects of Mildronate on the ability to drive vehicles and mechanisms.

Form of production

Capsules

Storage conditions

In a dry place, at a temperature not exceeding 25 °C

Shelf life

4 years

Active ingredient

Meldonium

Conditions of release from pharmacies

By prescription

Dosage form

of the capsule

Description

For adults as directed by your doctor

Indications

Heart Failure, Angina Pectoris, Myocardial Infarction, Hangover, Stroke Effects, Intense exercise

Weight

Weight: 71 g.